Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24536959 | 1.00 | KRAS (0.68) | KRAS | |
| SCHEMBL24536345 | 0.93 | KRAS (0.68) | KRAS | |
| SCHEMBL29679992 | 0.93 | KRAS (0.68) | KRAS | |
| SCHEMBL29680852 | 0.93 | KRAS (0.69) | KRAS | |
| SCHEMBL24536495 | 0.93 | KRAS (0.69) | KRAS | |
| SCHEMBL24537297 | 0.92 | KRAS (0.58) | KRAS | |
| SCHEMBL29680114 | 0.91 | KRAS (0.70) | KRAS | |
| SCHEMBL24535736 | 0.91 | KRAS (0.70) | KRAS | |
| SCHEMBL24536502 | 0.91 | KRAS (0.71) | KRAS | |
| SCHEMBL29680763 | 0.91 | KRAS (0.71) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384177-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117897159-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |